Key highlights
- Collaboration with Novelty Nobility to advance NN4101 bispecific antibody development, with activities starting May 2026.
- Copenhagen facility completed cell‑line development and Master Cell Bank; GMP manufacturing will proceed at Chiba facility in Japan.
- AGC Biologics will leverage its cGMP network across Japan, the United States and Europe to support tech transfer and flexible manufacturing.
Project overview
AGC Biologics and South Korea’s Novelty Nobility have launched a development and manufacturing project for NN4101, a bispecific antibody candidate for retinal neovascular diseases, with activities starting in May 2026.
Technical progress and manufacturing plan
Cell‑line development and a Master Cell Bank were completed at AGC’s Copenhagen facility; GMP manufacturing and further process development will proceed at the Chiba facility in Japan, reflecting the need for advanced process control and stringent quality management for bispecific formats.
Global operations and technology transfer
AGC Biologics will leverage its cGMP facilities across Japan, the United States and Europe to support technology transfer and provide flexible manufacturing solutions aligned to customer development and production requirements.
